CARD10: A Potential Drug Target and Biomarker for Bcl10-Binding Protein and Activator of NFKB

Target Name: CARD10

NCBI ID: G29775

CARD10

CARD10: A Potential Drug Target and Biomarker for Bcl10-Binding Protein and Activator of NFKB

The Bcl10 protein is a key regulator of apoptosis, a critical cellular process that helps remove damaged or dysfunctional cells from the body. The Bcl10 gene has been implicated in various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. The NFKB pathway, a critical signaling pathway involved in inflammation and stress responses, is a potential target for Bcl10. The NFKB pathway is activated by various factors, including Bcl10, which can induce its activity to promote cell survival and proliferation.

CARD10: A protein that binds to Bcl10 and activates NFKB

The CARD10 protein is a critical regulator of the NFKB pathway. It is a protein that binds to the Bcl10 protein and activates its activity. CARD10 has been shown to play a crucial role in the regulation of cell survival and proliferation. It is a NFKB-activating protein that can induce the activity of NFKB to promote cell survival and proliferation.

CARD10 has been shown to have various functions, including regulating cell apoptosis, cell cycle progression, and cell survival. It has been shown to promote the growth and proliferation of various cell types, including cancer cells. CARD10 has also been shown to play a role in the regulation of inflammation and immune responses.

Potential drug targeting

The CARD10 protein is a potential drug target for various diseases. Its activity in promoting cell survival and proliferation makes it an attractive target for cancer therapies. CARD10 has been shown to promote the growth and survival of various cancer cell types, making it an attractive target for cancer therapies.

In addition to its role in cancer, CARD10 has also been implicated in the regulation of neurodegenerative diseases and autoimmune disorders. Its activity in promoting cell survival and proliferation in neurodegenerative diseases and autoimmune disorders makes it a potential target for these therapies.

CARD10 as a biomarker

CARD10 has also been shown to be a potential biomarker for various diseases. Its activity in promoting cell survival and proliferation makes it an attractive target for biomarkers that can be used to diagnose and monitor diseases.

CARD10 has been shown to be involved in the regulation of cell apoptosis, which is a critical cellular process that helps remove damaged or dysfunctional cells from the body. Its activity in regulating cell apoptosis makes it an attractive target for biomarkers that can be used to diagnose and monitor diseases associated with cellular dysfunction.

Conclusion

In conclusion, the CARD10 protein is a potential drug target and biomarker for various diseases. Its activity in promoting cell survival and proliferation makes it an attractive target for cancer therapies. Its activity in regulating the NFKB pathway makes it a potential target for diseases associated with cellular dysfunction. Further research is needed to fully understand the role of CARD10 in diseases and its potential as a drug target and biomarker.

Protein Name: Caspase Recruitment Domain Family Member 10

Functions: Scaffold protein that plays an important role in mediating the activation of NF-kappa-B via BCL10 or EGFR

The "CARD10 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CARD10 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets